DK1689737T3 - Beta-lactamer til behandling af sygdomme i CNS - Google Patents

Beta-lactamer til behandling af sygdomme i CNS

Info

Publication number
DK1689737T3
DK1689737T3 DK04797809T DK04797809T DK1689737T3 DK 1689737 T3 DK1689737 T3 DK 1689737T3 DK 04797809 T DK04797809 T DK 04797809T DK 04797809 T DK04797809 T DK 04797809T DK 1689737 T3 DK1689737 T3 DK 1689737T3
Authority
DK
Denmark
Prior art keywords
lactams
beta
treatment
cns diseases
cns
Prior art date
Application number
DK04797809T
Other languages
English (en)
Inventor
Giuseppe Alvaro
Fabio Romano Di
Riccardo Giovannini
Alfredo Paio
Maria Elvira Tranquillini
Lucia Mattioli
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1689737T3 publication Critical patent/DK1689737T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
DK04797809T 2003-11-12 2004-11-10 Beta-lactamer til behandling af sygdomme i CNS DK1689737T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0326407.4A GB0326407D0 (en) 2003-11-12 2003-11-12 Chemical compounds
PCT/EP2004/012772 WO2005049600A1 (en) 2003-11-12 2004-11-10 Beta-lactams for treatment of cns disorders

Publications (1)

Publication Number Publication Date
DK1689737T3 true DK1689737T3 (da) 2008-10-27

Family

ID=29726427

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04797809T DK1689737T3 (da) 2003-11-12 2004-11-10 Beta-lactamer til behandling af sygdomme i CNS

Country Status (27)

Country Link
US (1) US20080262041A1 (da)
EP (1) EP1689737B1 (da)
JP (1) JP2007510692A (da)
KR (1) KR20060118477A (da)
CN (1) CN1878764A (da)
AR (1) AR046233A1 (da)
AT (1) ATE401321T1 (da)
AU (1) AU2004291296B2 (da)
BR (1) BRPI0416285A (da)
CA (1) CA2546007A1 (da)
CY (1) CY1108404T1 (da)
DE (1) DE602004015144D1 (da)
DK (1) DK1689737T3 (da)
ES (1) ES2310295T3 (da)
GB (1) GB0326407D0 (da)
HR (1) HRP20080501T3 (da)
IL (1) IL175279A0 (da)
IS (1) IS8477A (da)
MA (1) MA28156A1 (da)
MY (1) MY138378A (da)
NO (1) NO20062661L (da)
PL (1) PL1689737T3 (da)
PT (1) PT1689737E (da)
RU (1) RU2006120417A (da)
SI (1) SI1689737T1 (da)
TW (1) TW200528439A (da)
WO (1) WO2005049600A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101347278B1 (ko) * 2006-01-24 2014-01-03 바이오시그널 리미티드 신규한 락탐 화합물
AU2015200142B2 (en) * 2006-01-24 2016-07-07 Unilever Plc Novel lactams

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL262366A (da) * 1960-03-14
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
EP0545478A1 (en) * 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
GB9200535D0 (en) * 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
US5824690A (en) * 1993-05-06 1998-10-20 Hoechst Marion Roussel Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
DK0777666T3 (da) * 1994-08-25 1999-09-27 Merrell Pharma Inc Substituerede piperidiner anvendelige ved behandling af allergiske sygdomme
US5780466A (en) * 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
US6211199B1 (en) * 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
FR2779429B1 (fr) * 1998-06-03 2000-07-13 Synthelabo Derives d'oxindole, leurs preparations et leurs applications en therapeutique
US6204265B1 (en) * 1998-12-23 2001-03-20 Schering Corporation Substituted oximes and hydrazones as neurokinin antagonists
GB0114867D0 (en) * 2001-06-18 2001-08-08 Merck Sharp & Dohme Therapeutic agents
GB0412865D0 (en) * 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
US20080262041A1 (en) 2008-10-23
EP1689737B1 (en) 2008-07-16
EP1689737A1 (en) 2006-08-16
CN1878764A (zh) 2006-12-13
MY138378A (en) 2009-05-29
CY1108404T1 (el) 2014-02-12
RU2006120417A (ru) 2007-12-27
PL1689737T3 (pl) 2008-12-31
CA2546007A1 (en) 2005-06-02
PT1689737E (pt) 2008-10-24
AR046233A1 (es) 2005-11-30
AU2004291296B2 (en) 2011-04-07
SI1689737T1 (sl) 2008-12-31
ATE401321T1 (de) 2008-08-15
ES2310295T3 (es) 2009-01-01
HRP20080501T3 (en) 2008-11-30
AU2004291296A1 (en) 2005-06-02
IS8477A (is) 2006-05-22
NO20062661L (no) 2006-06-09
KR20060118477A (ko) 2006-11-23
BRPI0416285A (pt) 2007-01-23
GB0326407D0 (en) 2003-12-17
DE602004015144D1 (de) 2008-08-28
JP2007510692A (ja) 2007-04-26
WO2005049600A1 (en) 2005-06-02
IL175279A0 (en) 2006-09-05
HK1094698A1 (en) 2007-04-04
TW200528439A (en) 2005-09-01
MA28156A1 (fr) 2006-09-01

Similar Documents

Publication Publication Date Title
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DK1716162T3 (da) Phosphonater, amidomonophosphonater, amidobisphosphonater til behandling af virussygdomme
DK1478358T3 (da) Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1663287T3 (da) Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
NO20052223D0 (no) Tiazolforbindelser for behandling av neurodegenerative forstyrrelser
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1592384T3 (da) Cop 1 til behandling af inflammatoriske tarmsygdomme
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
DK1708991T3 (da) Sulfonamid derivater til behandling af sygdomme
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
FI20060154L (fi) Neurogeneratiivisten tilojen hoito
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1727801T3 (da) Til behandling af smerter anvendelige piperaziner
NO20044814L (no) Fremgangsmate for fremstilling av combretastaniner
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
DK1678135T3 (da) Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser
DK1572613T3 (da) Fremgangsmåde til fremstilling af benzophenoner
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose